Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 13, 2015, Pages 2233-2240.e2

  Jones, Jennifer L ^a   Kaplan, Gilaad G ^b   Peyrin Biroulet, Laurent ^c   Baidoo, Leonard ^d   Devlin, Shane ^b   Melmed, Gil Y ^e   Tanyingoh, Divine ^b   Raffals, Laura ^f   Irving, Peter ^g   Kozuch, Patricia ^h   Sparrow, Miles ⁱ   Velayos, Fernando ^j   Bressler, Brian ^k   Cheifetz, Adam ^l   Colombel, Jean Frederic ^m   Siegel, Corey A ⁿ  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITÉ DE LORRAINE   (France)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

^f MAYO CLINIC   (United States)

^g GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^h THOMAS JEFFERSON UNIVERSITY   (United States)

ⁱ ALFRED HOSPITAL   (Australia)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^l BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^m MOUNT SINAI SCHOOL OF MEDICINE   (United States)

ⁿ DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

more..

Author keywords

Clinical Trial; IBD; Immune Suppression; Inflammatory Bowel Disease

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; IMMUNOMODULATING AGENT; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; IMMUNOLOGIC FACTOR; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CLINICAL EFFECTIVENESS; CROHN DISEASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INJECTION SITE REACTION; META ANALYSIS; MONOTHERAPY; OUTCOME ASSESSMENT; REMISSION; SYSTEMATIC REVIEW; TREATMENT DURATION; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; COMBINATION DRUG THERAPY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; PATHOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

CROHN DISEASE; DRUG THERAPY, COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; IMMUNOLOGIC FACTORS; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84947422075     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2015.06.034     Document Type: Article

References (38)

1. Sandborn W.J., Feagan B.G., Stoinov S., et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007, 357:228-238.
2. Sandborn W.J., Hanauer S.B., Rutgeerts P., et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007, 56:1232-1239.
3. Sandborn W.J., Rutgeerts P., Enns R., et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007, 146:829-838.
4. Sands B.E., Anderson F.H., Bernstein C.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004, 350:876-885.
5. Schreiber S., Khaliq-Kareemi M., Lawrance I.C., et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007, 357:239-250.
6. Schreiber S., Rutgeerts P., Fedorak R.N., et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005, 129:807-818.
7. Targan S.R., Hanauer S.B., van Deventer S.J., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease: Crohn's Disease cA2 Study Group. N Engl J Med 1997, 337:1029-1035.
8. Colombel J.F., Sandborn W.J., Rutgeerts P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
9. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
10. Hanauer S.B., Sandborn W.J., Rutgeerts P., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006, 130:323-333. quiz 591.
11. Present D.H., Rutgeerts P., Targan S., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999, 340:1398-1405.
12. Rutgeerts P., D'Haens G., Targan S., et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999, 117:761-769.
13. Melmed G.Y., Spiegel B.M., Bressler B., et al. The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all. Clin Gastroenterol Hepatol 2010, 8:655-659.
14. Colombel J.F., Feagan B.G., Sandborn W.J., et al. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis 2012, 18:349-358.
15. Hazlewood G.S., Rezaie A., Borman M., et al. Comparative effectiveness of immunosuppressant and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis. Gastroenterology 2015, 148:344-354.
16. Lichtenstein G.R., Diamond R.H., Wagner C.L., et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009, 30:210-226.
17. Toruner M., Loftus E.V., Harmsen W.S., et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008, 134:929-936.
18. Siegel C.A., Marden S.M., Persing S.M., et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009, 7:874-881.
19. Colombel J.F., Sandborn W.J., Reinisch W., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362:1383-1395.
20. Lakatos P.L., Lovasz B.D., David G., et al. The risk of lymphoma and immunomodulators in patients with inflammatory bowel diseases: results from a population-based cohort in Eastern Europe. J Crohns Colitis 2013, 7:385-391.
21. Kotlyar D.S., Osterman M.T., Diamond R.H., et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011, 9:36-41.
22. Osterman M.T., Sandborn W.J., Colombel J.F., et al. Increased risk of malignancy with adalimumab combination therapy, compared to monotherapy, for Crohn's disease. Gastroenterology 2013, 146:941-949.
23. Mazor Y., Kopylov U., Ben Hur D. Evaluating adalimumab drug and antibody levels and predictors of clinical and laboratory response in Crohn's disease. Gastroenterology 2013, 144:S-778.
24. Karmiris K., Paintaud G., Noman M., et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009, 137:1628-1640.
25. Ben-Bassat O., Hauenstein S., Iacono A. Serum adalimumab and immunogenicity in IBD patients after 80 mg biweekly maintenance therapy. Gastroenterology 2013, 144:S-771.
26. Imaeda I., Takahash K., Fujimoto T. Accurate determination of serum adalimumab and anti-adalimumab antibodies drug levels during maintenance therapy for Crohn's disease. Gastroenterology 2013, 144:S-431.
27. Breedveld F.C., Weisman M.H., Kavanaugh A.F., et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006, 54:26-37.
28. Sands B., Anderson F., Bernstein C., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004, 350:876-885.
29. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
30. Maser E.A., Villela R., Silverberg M.S., et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006, 4:1248-1254.
31. Garimella T, Peng J, Beck K. Pharmacokinetics of adalimumab in a long-term investigation of the induction and maintenance of remission in patients with Crohn's disease (CLASSIC I and CLASSIC II). Presented at Digestive Diseases Week, 2006.
32. Chiu Y.L., Rubin D.T., Vermeire S., et al. Serum adalimumab concentration and clinical remission in patients with Crohn's disease. Inflamm Bowel Dis 2013, 19:1112-1122.
33. Bartelds G.M., Krieckaert C.L., Nurmohamed M.T., et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011, 305:1460-1468.
34. Bartelds G.M., Wijbrandts C.A., Nurmohamed M.T., et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007, 66:921-926.
35. Krieckaert C.L., Nurmohamed M.T., Wolbink G.J. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis 2012, 71:1914-1915.
36. Bouguen G., Sninsky C., Tang K.L., et al. Change in erythrocyte mean corpuscular volume during combination therapy with azathioprine and infliximab is associated with mucosal healing: a post hoc analysis from SONIC. Inflamm Bowel Dis 2015, 21:606-614.
37. Yarur A.J., Kubiliun M.J., Czul F., et al. Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy. Clin Gastroenterol Hepatol 2015, 13:1118-1124.
38. Dulai P.S., Siegel C.A., Colombel J.F., et al. Systematic review: monotherapy with antitumour necrosis factor alpha agents versus combination therapy with an immunosuppressive for IBD. Gut 2014, 63:1843-1853.